1
Conclusion and Relevance: The currently approved ertapenem dose imposes a risk of developing neurotoxicity in patients with CKD-5D.
2
No patients had grade 1 or higher thrombocytopenia, and although 44% of the patients developed neurotoxicity, all cases remained grade 1.
3
The patients who developed neurotoxicity were all male; mean age was 74 ±9 years as compared with 68.9 ± 13 years in the sample.